Metformin
( DrugBank: Metformin / KEGG DRUG: Metformin hydrochloride, Metformin )
25 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
| 6 | パーキンソン病 | 3 |
| 8 | ハンチントン病 | 1 |
| 13 | 多発性硬化症／視神経脊髄炎 | 7 |
| 46 | 悪性関節リウマチ | 9 |
| 49 | 全身性エリテマトーデス | 4 |
| 60 | 再生不良性貧血 | 1 |
| 65 | 原発性免疫不全症候群 | 1 |
| 67 | 多発性嚢胞腎 | 5 |
| 75 | クッシング病 | 3 |
| 77 | 下垂体性成長ホルモン分泌亢進症 | 2 |
| 81 | 先天性副腎皮質酵素欠損症 | 1 |
| 86 | 肺動脈性肺高血圧症 | 2 |
2. 筋萎縮性側索硬化症
臨床試験数 : 786 / 薬物数 : 550 - (DrugBank : 182) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
6. パーキンソン病
臨床試験数 : 2,586 / 薬物数 : 1,871 - (DrugBank : 354) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
8. ハンチントン病
臨床試験数 : 276 / 薬物数 : 185 - (DrugBank : 58) / 標的遺伝子数 : 86 - 標的パスウェイ数 : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. 悪性関節リウマチ
臨床試験数 : 4,543 / 薬物数 : 2,251 - (DrugBank : 390) / 標的遺伝子数 : 198 - 標的パスウェイ数 : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. 全身性エリテマトーデス
臨床試験数 : 1,227 / 薬物数 : 752 - (DrugBank : 175) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
60. 再生不良性貧血
臨床試験数 : 305 / 薬物数 : 328 - (DrugBank : 91) / 標的遺伝子数 : 60 - 標的パスウェイ数 : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. 原発性免疫不全症候群
臨床試験数 : 798 / 薬物数 : 585 - (DrugBank : 118) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 216
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. 多発性嚢胞腎
臨床試験数 : 233 / 薬物数 : 188 - (DrugBank : 54) / 標的遺伝子数 : 60 - 標的パスウェイ数 : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
75. クッシング病
臨床試験数 : 225 / 薬物数 : 167 - (DrugBank : 49) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
77. 下垂体性成長ホルモン分泌亢進症
臨床試験数 : 351 / 薬物数 : 241 - (DrugBank : 28) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 102 / 薬物数 : 72 - (DrugBank : 18) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 71
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
86. 肺動脈性肺高血圧症
臨床試験数 : 1,288 / 薬物数 : 565 - (DrugBank : 126) / 標的遺伝子数 : 81 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. 潰瘍性大腸炎
臨床試験数 : 3,305 / 薬物数 : 1,646 - (DrugBank : 318) / 標的遺伝子数 : 165 - 標的パスウェイ数 : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
113. 筋ジストロフィー
臨床試験数 : 766 / 薬物数 : 477 - (DrugBank : 119) / 標的遺伝子数 : 80 - 標的パスウェイ数 : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
127. 前頭側頭葉変性症
臨床試験数 : 123 / 薬物数 : 107 - (DrugBank : 33) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 89
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
158. 結節性硬化症
臨床試験数 : 129 / 薬物数 : 56 - (DrugBank : 20) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
206. 脆弱Ｘ症候群
臨床試験数 : 118 / 薬物数 : 75 - (DrugBank : 30) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
218. アルポート症候群
臨床試験数 : 41 / 薬物数 : 32 - (DrugBank : 19) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 44
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
225. 先天性腎性尿崩症
臨床試験数 : 17 / 薬物数 : 40 - (DrugBank : 19) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
233. ウォルフラム症候群
臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 6) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 6
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
265. 脂肪萎縮症
臨床試験数 : 127 / 薬物数 : 137 - (DrugBank : 58) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
285. ファンコニ貧血
臨床試験数 : 69 / 薬物数 : 109 - (DrugBank : 37) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 169
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. 嚢胞性線維症
臨床試験数 : 1,826 / 薬物数 : 1,271 - (DrugBank : 246) / 標的遺伝子数 : 118 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
301. 黄斑ジストロフィー
臨床試験数 : 59 / 薬物数 : 42 - (DrugBank : 14) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 72
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|